The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China

Gu, Mianmian; Hao, Xiaohong; Cong, Lin; Sun, Jie

doi:10.1097/md.0000000000018196

Cited by 16 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that patients with hematological cancers experience anxiety and depression [36,37]. Studies also suggest the same effects on patients with hematological relapse [38,39], which is not surprising given that they face yet another life-threatening situation. Fear of recurrence has been reported as a major concern for this patient population after treatment completion [36,40,41] and would be expected to lead to anxiety, as would relapse when it is diagnosed.…”

Section: Results In a Clinical Contextmentioning

confidence: 87%

Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study

Sommer

Nielsen

et al. 2021

Health Qual Life Outcomes

View full text Add to dashboard Cite

Background Patients with hematological cancer who experience relapse or progressive disease often face yet another line of treatment and continued mortality risk that could increase their physical and emotional trauma and worsen their health-related quality of life. Healthcare professionals who use patient-reported outcomes to identify who will have specific sensitivities in particular health-related quality of life domains may be able to individualize and target treatment and supportive care, both features of precision medicine. Here, in a cohort of patients with relapsed or progressive hematological cancer, we sought to identify health-related quality of life domains in which they experienced deterioration after relapse treatment and to investigate health-related quality of life patterns. Method Patients were recruited in connection with a precision medicine study at the Department of Hematology, Aalborg University Hospital. They completed the European Organization for Research and Treatment of Cancer questionnaire and the Hospital Anxiety and Depression Scale at baseline and at 3, 6, 9, and 12 months after the relapse diagnosis or progressive cancer. Modes of completion were electronically or on paper. Clinically relevant changes from baseline to 12 months were interpreted according to Cocks’ guidelines. We quantified the number of patients with moderate or severe symptoms and functional problems and the number who experienced improvements or deterioration from baseline to 12 months. Results A total of 104 patients were included, of whom 90 (87%) completed baseline questionnaires and 50 (56%) completed the 12-month assessments. The three symptoms that patients most often reported as deteriorating were fatigue (18%), insomnia (18%), and diarrhea (18%). The three functions that patients most often reported as deteriorating were role (16%) and emotional (16%) and cognitive (16%) functioning. Conclusion In this study, patient-reported outcome data were useful for identifying negatively affected health-related quality of life domains in patients with relapsed or progressive hematological cancer. We identified patients experiencing deterioration in health-related quality of life during treatment and characterized a potential role for patient-reported outcomes in precision medicine to target treatment and supportive care in this patient group.

show abstract

Section: Results In a Clinical Contextmentioning

confidence: 87%

Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study

Sommer

Nielsen

et al. 2021

Health Qual Life Outcomes

View full text Add to dashboard Cite

show abstract

“…After enrollment, the anxiety and depression of participants were assessed using the Hospital Anxiety and Depression Scale (HADS). 19 , 20 , 21 After given description of scale filling by the investigator, participants were required to complete the HADS by themselves. Then, researchers assessed the anxiety and depression of participants using HADS.…”

Section: Methodsmentioning

confidence: 99%

Serum tumor necrosis factor‐α, interleukin‐1β, interleukin‐6, and interleukin‐17 relate to anxiety and depression risks to some extent in non‐small cell lung cancer survivor

Liu

Yao

Liu

2021

Clinical Respiratory J

View full text Add to dashboard Cite

Introduction: Inflammatory cytokines are proposed as modulators for the pathogenesis of anxiety and depression (anxiety/depression), and anxiety/ depression are frequently existed in non-small cell lung cancer (NSCLC) survivors. However, no published study has explored the association of inflammation cytokines with anxiety/depression in NSCLC survivors. Objectives: We aimed to evaluate serum tumor necrosis factor-α (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interleukin-17 (IL-17) levels, and their correlations with anxiety/depression in NSCLC survivors.Methods: Totally, 217 NSCLC survivors and 200 controls were recruited.Then, inflammatory cytokines in serum samples were detected by enzymelinked immunosorbent assay (ELISA). Besides, their anxiety/depression status was assessed by Hospital Anxiety and Depression Scale (HADS). Results: HADS-anxiety score, anxiety rate, anxiety severity, HADS-depression score, depression rate, and depression severity were all increased in NSCLC survivors compared with controls (all P < 0.001). Regarding inflammatory cytokines, TNF-α, IL-1β, and IL-17 levels were higher (all P < 0.01), while IL-6 (P = 0.105) level was of no difference in NSCLC survivors compared with controls. Furthermore, TNF-α, IL-1β, IL-6, and IL-17 were all positively associated with HADS-A score (all P < 0.05), anxiety occurrence (all P < 0.05), HADS-D score (all P < 0.05), and depression occurrence (all P < 0.05) in NSCLC survivors, while the correlation-coefficients were weak. Additionally, multivariate logistic regression analyses disclosed that TNF-α (both P < 0.05) and IL-1β (both P < 0.001) were independently correlated with increased anxiety and depression risks in NSCLC survivors. Conclusion: Serum TNF-α, IL-1β, IL-6, and IL-17 are related to increased anxiety and depression risks to some extent in NSCLC survivors.Meifang Liu and Xuesong Liu contributed equally to this work.

show abstract

“…During follow-up, anxiety, and depression of the patients were assessed using HADS at baseline (M0), month 3 (M3), month 6 (M6), month 9 (M9), month 12 (M12), month 15 (M15), month 18 (M18), month 21 (M21), month 24 (M24), month 27 (M27), month 30 (M30), month 33 (M33), and month 36 (M36). [15][16][17] The HADS has 14 items: 7 items were designed for anxiety measuring HADSanxiety (HADS-A) and other 7 items were designed for depression measuring HADS-depression (HADS-D). The total score of HADS-A was ranging from 0 to 21, and the total score ≥8 was defined as anxiety.…”

Section: Treatment Follow-up and Assessmentmentioning

confidence: 99%

Longitudinal assessment of anxiety/depression rates and their related predictive factors in acute ischemic stroke patients

et al. 2021

View full text Add to dashboard Cite

This study aimed at investigating the longitudinal changes of poststroke anxiety/depression rates, and their potential risk factors in acute ischemic stroke (AIS) patients. A total of 250 first diagnosis of AIS patients were enrolled and followed for 36 months. Anxiety/depression of patients were assessed using hospital anxiety and depression scale (HADS) at month (M) 0 (M0) and then every 3 months till M36. During 36-month follow-up, both HADS-anxiety score (from 6.9 ± 3.1 at M0 to 8.0 ± 3.5 at M36) and anxiety rate (from 41.2% at M0 to 54.0% at M36) (both P < .01) were increased with time longitudinally. Meanwhile, HADS-depression score (from 6.2 ± 3.0 at M0 to 6.9 ± 3.1 at M36) and depression rate (from 32.4% at M0 to 40.4% at M36) (both P > .05) displayed an upward trend with time longitudinally but without statistical significance. By forward multivariate logistic regression analysis, female, diabetes and higher National Institute of Health Stroke Scale (NIHSS) score independently predicted elevated anxiety risk at M0, M12, M24, and M36 (all P < .05); while longer education duration and hypertension independently predicted raised anxiety risk at M0 and M12 (all P < .05), respectively. Regarding depression, diabetes independently predicted increased depression risk at M0, M12, M24, and M36 (all P < .01); longer education duration independently predicted higher depression risk at M0 and M12 (both P < .05); female independently predicted increased depression risk at M24 and M36 (both P < .01); higher NIHSS score independently predicted raised depression risk at M24 and M36 (both P < .01). Poststroke anxiety and depression are frequent, which deteriorate with time; besides, female, diabetes, NIHSS score, hypertension and education duration independently predicted increased poststroke anxiety or depression risk in AIS patients.

show abstract

The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China

Cited by 16 publications

References 24 publications

Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study

Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study

Serum tumor necrosis factor‐α, interleukin‐1β, interleukin‐6, and interleukin‐17 relate to anxiety and depression risks to some extent in non‐small cell lung cancer survivor

Longitudinal assessment of anxiety/depression rates and their related predictive factors in acute ischemic stroke patients

Contact Info

Product

Resources

About